PCSK9 | Search Results | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Search Results for 'PCSK9 '

Injectable inclisiran (siRNA) as 3rd anti-PCSK9 behind mAbs Repatha and Praluent

Posted in Atherogenic Processes & Pathology, Drug Delivery Platform Technology, Exosomes: Natural Carriers for siRNA Delivery, FDA Regulatory Affairs, Frontiers in Cardiology and Cardiovascular Disorders, Gene Therapy & Gene Editing Development, Genome Biology, Genomics Pharmacy, Origins of Cardiovascular Disease, Pharmacotherapy of Cardiovascular Disease on November 18, 2019| Leave a Comment »

Injectable inclisiran (siRNA) as 3rd anti-PCSK9 behind mAbs Repatha and Praluent Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 4/27/2021 Combining AstraZeneca’s ‘good’ cholesterol booster with PCSK9 inhibition shows promise in heart disease by Angus Liu | Apr 21, 2021 3:00pm The drug, dubbed MEDI5884, is designed to neutralize a circulating enzyme called endothelial lipase. The protein regulates […]

Read Full Post »

Cholesterol-busting gut bacteria affect people’s cardiac health

Posted in Cell Biology, Metabolism, tagged Cholesterol, Coprostanol, gut bacteria, Metabolism, microbial gene on June 24, 2020| Leave a Comment »

Cholesterol-busting gut bacteria affect people’s cardiac health Reporter: Irina Robu, PhD Scientists at Broad Institute of MIT and Harvard University, has discovered a group a gut bacterium that can metabolize enough cholesterol to affect metabolism. Their study in Cell Host and Microbe, found that bacteria in the intestines have lower cholesterol levels in their blood. […]

Read Full Post »

Cholesterol Lowering Novel PCSK9 drugs: Praluent [Sanofi and Regeneron] vs Repatha [Amgen] – which drug cuts CV risks enough to make it cost-effective?

Posted in Atherogenic Processes & Pathology, Epigenetics and Cardiovascular Risks, Fatty acids, Frontiers in Cardiology and Cardiovascular Disorders, inflammation independent of lipid levels, Lipid metabolism, Lipidomics, Lipids, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Pharmaceutical R&D Informatics, Pharmacogenomics, Pharmacotherapy of Cardiovascular Disease, Systemic Inflammatory Diseases as CVD Risk, Value-based Drug Pricing on March 12, 2018| Leave a Comment »

Cholesterol Lowering Novel PCSK9 drugs: Praluent [Sanofi and Regeneron] vs Repatha [Amgen] – which drug cuts CV risks enough to make it cost-effective? Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 4/5/2022 Early PCSK9 Inhibition in AMI Yields Plaque Regression Ted Bosworth April 05, 2022 https://www.medscape.com/viewarticle/971582?spon=2&uac=93761AJ&impID=4140595&sso=true&faf=1&src=WNL_mdpls_220405_mscpedit_card https://www.mdedge.com/cardiology/article/253443/lipid-disorders/early-pcsk9-inhibition-ami-yields-plaque-regression UPDATED on 1/15/2019 In the patent fight over PCSK9 inhibitors, […]

Read Full Post »

ODYSSEY Outcomes trial evaluating the effects of a PCSK9 inhibitor, alirocumab, on major cardiovascular events in patients with an acute coronary syndrome to be presented at the American College of Cardiology meeting on March 10.

Posted in Atherogenic Processes & Pathology, Frontiers in Cardiology and Cardiovascular Disorders, Heart Failure (HF), inflammation independent of lipid levels, Lipid metabolism, Lipidomics, Lipids, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Pharmacotherapy of Cardiovascular Disease, tagged alirocumab on February 28, 2018| Leave a Comment »

ODYSSEY Outcomes trial evaluating the effects of a PCSK9 inhibitor, alirocumab, on major cardiovascular events in patients with an acute coronary syndrome to be presented at the American College of Cardiology meeting on March 10. Reporter: Aviva Lev-Ari, PhD, RN For PCSK9 inhibitors, the effect on major adverse cardiovascular events has always fallen short of expectations based on […]

Read Full Post »

FDA approval on 12/1/2017 of Amgen’s evolocumb (Repatha) a PCSK9 inhibitor for the prevention of heart attacks, strokes, and coronary revascularizations in patients with established cardiovascular disease

Posted in Atherogenic Processes & Pathology, Frontiers in Cardiology and Cardiovascular Disorders, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Pharmacotherapy of Cardiovascular Disease on December 1, 2017| Leave a Comment »

FDA approval on 12/1/2017 of Amgen’s evolocumb (Repatha) a PCSK9 inhibitor for the prevention of heart attacks, strokes, and coronary revascularizations in patients with established cardiovascular disease Reporter: Aviva Lev-Ari, PhD, RN Evolocumab was first FDA approved in 2015 for patients with familial hypercholesterolemia and others who fail to achieve LDL cholesterol lowering through diet and […]

Read Full Post »

19 of the 49 New Therapeutic Molecular Entities FDA approved in 2020 — as well as a new Cell-based therapy — are Personalized Medicines

Posted in FDA Regulatory Affairs, New Drug Approval, Personalized and Precision Medicine & Genomic Research on March 2, 2021| Leave a Comment »

19 of the 49 New Therapeutic Molecular Entities FDA approved in 2020 — as well as a new Cell-based therapy — are Personalized Medicines Reporter: Aviva Lev-Ari, PhD, RN 2020 DRUG APPROVALS 19 of the 49 new therapeutic molecular entities FDA approved in 2020 — as well as a new cell-based therapy — are […]

Read Full Post »

NEW GENRE Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases – Series A, Volume 5

Posted in on June 7, 2022|

Original Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases NEW GENRE Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-five-pharmacological-agents-in-treatment-of-cardiovascular-diseases-series-a-volume-5/ This volume has the following three parts: PART A: The eTOCs in Spanish in Audio format PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format PART C: The Editorials of the original e-Books in […]

Read Full Post »

Reversing Heart Disease: Combination of PCSK9 Inhibitors and Statins – Opinion by Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic

Reversing Heart Disease: Combination of PCSK9 Inhibitors and Statins – Opinion by Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 2/25/2019 https://www.medpagetoday.com/cardiology/prevention/78202?xid=nl_mpt_SRCardiology_2019-02-25&eun=g99985d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=CardioUpdate_022519&utm_term=NL_Spec_Cardiology_Update_Active While nearly 10% of middle-age adults in China have high risk for cardiovascular disease, only 0.6% of these high-risk individuals use statins and 2.4% […]

Read Full Post »

eProceedings – Day 1: Charles River Laboratories – 3rd World Congress, Delivering Therapies to the Clinic Faster, September 23 – 24, 2019, Cambridge, MA

Posted in Conference Coverage with Social Media, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Drug Carrier Design, Drug Delivery Platform Technology, Drug Development Process, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment on July 19, 2019| Leave a Comment »

eProceedings – Day 1: Charles River Laboratories – 3rd World Congress, Delivering Therapies to the Clinic Faster, September 23 – 24, 2019, 25 Edwin H. Land Boulevard, Cambridge, MA https://events.criver.com/event/9eab0ee1-982e-42c6-a4cd-fb43f9f2f1d0/confirmation:7c68cf9b-c599-469e-b602-42178c77e4f9 ANNOUNCEMENT Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover this event in Real Time for pharmaceuticalintelligence.com Confirmation Number: 8ZNCBYNGHCK In attendance […]

Read Full Post »

A new mechanism of action to attack in the treatment of coronary artery disease (CAD), Novartis developed Ilaris (canakinumab) a human monoclonal antibody targeting the interleukin-1beta innate immunity pathway

Posted in Acute Myocardial Infarction, Cardiovascular Research, Frontiers in Cardiology and Cardiovascular Disorders, Heart Failure (HF), inflammation independent of lipid levels, Origins of Cardiovascular Disease, Pharmacotherapy of Cardiovascular Disease, Stroke, Vascular Diseases, tagged Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), human monoclonal antibody targeting the interleukin-1beta innate immunity pathway on April 6, 2018| Leave a Comment »

A new mechanism of action to attack in the treatment of coronary artery disease (CAD), Novartis developed Ilaris (canakinumab), a human monoclonal antibody targeting the interleukin-1beta innate immunity pathway Reporter: Aviva Lev-Ari, PhD, RN Speaking at an ESC press briefing, Ridker said, “This is what personalized predictive medicine is all about.” Once a patient has […]